Kennedy Capital Management, Inc. Celldex Therapeutics, Inc. Transaction History

Kennedy Capital Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$35.22 - $51.88 $1.01 Million - $1.48 Million	-28,586 Reduced 45.98%	33,586 $1.41 Million
Q4 2023 Feb 14, 2024	SELL	$22.61 - $40.65 $570,269 - $1.03 Million	-25,222 Reduced 28.86%	62,172 $2.47 Million
Q3 2023 Nov 14, 2023	BUY	$25.45 - $37.46 $4,224 - $6,218	166 Added 0.19%	87,394 $2.41 Million
Q2 2023 Aug 14, 2023	BUY	$30.29 - $38.28 $177,559 - $224,397	5,862 Added 7.2%	87,228 $2.96 Million
Q1 2023 May 15, 2023	BUY	$34.78 - $47.43 $1,634 - $2,229	47 Added 0.06%	81,366 $2.93 Million
Q4 2022 Feb 14, 2023	SELL	$27.78 - $45.38 $861 - $1,406	-31 Reduced 0.04%	81,319 $3.62 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $1.29 Million - $2.14 Million	57,034 Added 234.55%	81,350 $2.29 Million
Q2 2022 Aug 10, 2022	SELL	$20.5 - $37.33 $4,120 - $7,503	-201 Reduced 0.82%	24,316 $656,000
Q1 2022 May 16, 2022	SELL	$27.64 - $39.32 $100,637 - $143,164	-3,641 Reduced 12.93%	24,517 $835,000
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $1 Million - $1.58 Million	28,158 New	28,158 $1.09 Million

197

69.7M

960K

675K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $919M
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.